%PDF-1.4
%
94 0 obj
<>
endobj
158 0 obj
<>/Font<>>>/Fields[]>>
endobj
91 0 obj
<>
endobj
185 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-01-13T14:44:04Z
2024-03-28T12:44:06-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T12:44:06-07:00
application/pdf
Heather
2002-478.suppl.65
uuid:a69be360-1dd1-11b2-0a00-820827bd7700
uuid:a69be363-1dd1-11b2-0a00-900000000000
endstream
endobj
80 0 obj
<>
endobj
81 0 obj
<>
endobj
95 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 60 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 62 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 64 0 R/Type/Page>>
endobj
12 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 66 0 R/Type/Page>>
endobj
35 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 68 0 R/Type/Page>>
endobj
48 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 70 0 R/Type/Page>>
endobj
51 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 72 0 R/Type/Page>>
endobj
211 0 obj
[216 0 R]
endobj
212 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 8 0 0 8 72 714.5293 Tm
[(receptor)20 (-associated factor \(TRAF\) family: adapter proteins that)]TJ
0 -1.25 TD
(mediate cytokine signaling. Exp Cell Res 2000;254:14-24.)Tj
-1.875 -1.25 Td
[(37.)-625 (Gravallese EM, Galson DL, Goldring SR, )55 (Auron PE. )18 (The role of)]TJ
1.875 -1.25 Td
[(TNF-receptor family members and other )18 (TRAF-dependent receptors)]TJ
T*
[(in bone resorption. )55 (Arthritis Res 2001;3:6-12.)]TJ
-1.875 -1.25 Td
[(38.)-625 (Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles)]TJ
1.875 -1.25 Td
(and possible application of its selective inhibitors. Inflamm Res)Tj
0 Tc 0 Tw T*
(2000;49:367-92.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(39.)-625 (Jamal OS, Conaghan PG, Cunningham )55 (AM, et al. Increased)]TJ
1.875 -1.25 Td
[(expression of human type IIa secretory phospholipase )55 (A)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 253.1091 621.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 257.9091 624.5293 Tm
(antigen in)Tj
0 Tc -23.2386 -1.25 Td
[(arthritic synovium. )55 (Ann Rheum Dis 1998;57:550-8.)]TJ
-0.00011 Tc -1.875 -1.25 Td
[(40.)-625 (Siegle I, Klein )18 (T)74 (, Backman JT)74 (, Saal JG, Nusing RM, Fritz P)111 (.)]TJ
1.875 -1.25 Td
(Expression of cyclooxygenase 1 and cyclooxygenase 2 in human)Tj
T*
[(synovial tissue: dif)18 (ferential elevation of cyclooxygenase 2 in )]TJ
T*
[(inflammatory joint diseases. )55 (Arthritis Rheum 1998;41:122-9.)]TJ
-1.875 -1.25 Td
[(41.)-625 (Stichtenoth DO, )18 (Thoren S, Bian H, Peters-Golden M, Jakobsson PJ,)]TJ
1.875 -1.25 Td
[(Crof)18 (ford LJ. Microsomal prostaglandin E synthase is regulated by)]TJ
T*
(proinflammatory cytokines and glucocorticoids in primary )Tj
T*
(rheumatoid synovial cells. J Immunol 2001;167:469-74.)Tj
-1.875 -1.25 Td
[(42.)-625 (Bidgood MJ, Jamal OS, Cunningham )55 (AM, Brooks PM, Scott KF)80 (.)]TJ
1.875 -1.25 Td
[(T)70 (ype IIA)-220 (secretory phospholipase )55 (A)]TJ
0 Tc 0 Tw 5.2 0 0 5.2 187.7551 511.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 192.5551 514.5293 Tm
(up-regulates cyclooxygenase-2)Tj
-15.0694 -1.25 Td
(and amplifies cytokine-mediated prostaglandin production in human)Tj
T*
(rheumatoid synoviocytes. J Immunol 2000;165:2790-7.)Tj
-1.875 -1.25 Td
[(43.)-625 (Raisz LG. Prostaglandins and bone: physiology and)]TJ
1.875 -1.25 Td
[(pathophysiology)65 (. Osteoarthritis Cartilage 1999;7:419-21.)]TJ
-1.875 -1.25 Td
[(44.)-625 (Abramson SB. )18 (The role of COX-2 produced by cartilage in arthritis.)]TJ
1.875 -1.25 Td
(Osteoarthritis Cartilage 1999;7:380-1.)Tj
-1.875 -1.25 Td
[(45.)-625 (Miyaura C, Inada M, Suzawa )18 (T)74 (,)-275 (et al. Impaired bone resorption to)]TJ
1.875 -1.25 Td
(prostaglandin E)Tj
0 Tc 0 Tw 5.2 0 0 5.2 122.6297 431.8893 Tm
(2)Tj
-0.00011 Tc 0.02499 Tw 8 0 0 8 127.4297 434.5293 Tm
(in prostaglandin receptor EP4-knockout mice. )Tj
0 Tc -6.9287 -1.25 Td
(J Biol Chem 2000;275:19819-23.)Tj
-0.00011 Tc 31.125 36.25 Td
[(46.)-625 (Lotz M. )18 (The role of nitric oxide in articular cartilage damage.)]TJ
1.875 -1.25 Td
[(Rheum Dis Clin North )55 (Am 1999;25:269-82.)]TJ
-1.875 -1.25 Td
[(47.)-625 (Grabowski PS, Macpherson H, Ralston SH. Nitric oxide production)]TJ
1.875 -1.25 Td
(in cells derived from the human joint. Br J Rheumatol 1996;)Tj
0 Tc 0 Tw T*
(35:207-12.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(48.)-625 (Lotz M, Hashimoto S, Kuhn K. Mechanisms of chondrocyte )]TJ
1.875 -1.25 Td
(apoptosis. Osteoarthritis Cartilage 1999;7:389-91.)Tj
-1.875 -1.25 Td
[(49.)-625 (van\325)18 (t Hof RJ, )55 (Armour KJ, Smith LM, et al. Requirement of the)]TJ
1.875 -1.25 Td
(inducible nitric oxide synthase pathway for IL-1-induced)Tj
0.275 -1.25 Td
[(osteoclastic bone resorption. Proc Natl )55 (Acad Sci USA)]TJ
0 Tc 0 Tw -0.275 -1.25 Td
(2000;97:7993-8.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(50.)-625 (Bendele )55 (AM, Chlipala ES, Scherrer J, et al. Combination benefit of)]TJ
1.875 -1.25 Td
(treatment with the cytokine inhibitors interleukin-1 receptor)Tj
T*
(antagonist and PEGylated soluble tumor necrosis factor receptor)Tj
T*
[(type I in animal models of rheumatoid arthritis. )55 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2000;43:2648-59.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(51.)-625 (Coxon )55 (A, Bolon B, Estrada J, et al. Dif)18 (ferential control of )]TJ
1.875 -1.25 Td
(angiogenesis by anakinra \(IL-1ra\) and PEG sTNF-R1 [abstract].)Tj
T*
(Arthritis Rheum 2001;44 Suppl:S242.)Tj
-1.875 -1.25 Td
[(52.)-625 (Joosten LAB, Helsen MMA, Saxne )18 (T)74 (, van de Loo F)74 (A, Heinegard D,)]TJ
1.875 -1.25 Td
[(van den Ber)18 (g )18 (WB. IL-1)]TJ
/T1_1 1 Tf
0 Tc 0 Tw 9.5329 0 Td
(\003)Tj
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw [0.1 (\247 blockade prevents cartilage and bone)]TJ
-9.5328 -1.25 Td
(destruction in murine type II collagen-induced arthritis, whereas)Tj
-0.0002 Tc 0 Tw T*
(TNF-)Tj
/T1_1 1 Tf
0 Tc [-0.2 (\003)]TJ
/T1_0 1 Tf
-0.00011 Tc 0.02499 Tw 3.1273 0 Td
(blockade only ameliorates joint inflammation. J Immunol)Tj
0 Tc 0 Tw -3.1273 -1.25 Td
(1999;163:5049-55.)Tj
-0.00011 Tc 0.02499 Tw -1.875 -1.25 Td
[(53.)-625 (Schif)18 (f MH, Bulpitt K, )18 (W)80 (eaver )55 (AA, et al. Safety of combination)]TJ
1.875 -1.25 Td
[(therapy with anakinra and etanercept in patients with RA)-220 ([abstract].)]TJ
T*
(Arthritis Rheum 2001;44 Suppl:S79.)Tj
/T1_2 1 Tf
-35.1875 -52.3181 Td
[(Bingham: Cytokines in RA)-257 (bone degradation)]TJ
0 Tc 0 Tw 62.4375 -0.0313 Td
(9)Tj
ET
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
/GS1 gs
54 54 m
558 54 l
S
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 0 k
103.25 59.08 407.5 -10.83 re
f*
Q
Q
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
0 0 0 1 K
0.5 w
103.25 59.08 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
ET
/GS2 gs
BT
/T1_3 8 Tf
120.092 51 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2002. All rights reserved.)Tj
ET
Q
BT
0 g
/GS3 gs
/T1_4 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS3 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS3 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
72 0 obj
<>stream
8;Z\7$')nW#iu"-j?)+%1Vbt0h--t]8rV8q%>84Nd\o&B?O-E*4CErb8aU2C^Pd8\
S4'23AbQZ4@8TE`^(APD6kRX&%):hO"Dh-S`l'tU@6n;KS,H/Xfd5[Zn4mD:$he4g
G8+Th1kE7*Lm,'$FeSV0g^"lE>[RJ8,aOgdcd0'QaX,cN=N
EEhr86;J!V^GLY\6gN(b4X'Hd,Ml.='i"DehaH1`P#mnb.NZN7`60cQCO&3FK>DtcP@+g)
Q\SW/#@To
endstream
endobj
78 0 obj
[/Indexed/DeviceRGB 255 77 0 R]
endobj
77 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
100 0 obj
<>
endobj
109 0 obj
<>
endobj
98 0 obj
<>
endobj
141 0 obj
<>
endobj
190 0 obj
<>
endobj
97 0 obj
<>
endobj
133 0 obj
<>stream
HlUyPSy~KQ\Bc1W( * H $!$D. @/T
qqٙYF~[Q短ꪯ꯫ǜ0ǽFDEds$)Y NL Ls|Fwsfܼ
76؎#w#qo?r<4t>/44,B+ 3$9?_2Mn%l17*gP+Hi<.weVW|Q#c@MJD)i^p7Z#rܕk)9i"KSł4AH_1ad'}J`<'l3VQX4[F`$2.NzbNyT#%KQc.!.-.O&%Lz6ms&pB8SM91u;۽Rbw^K.o_o}9W.a2p<_;rn0Eą.RJTQQ\]$.RkbCܷ8tFy ᖍlj",Mj
Ra jOG YIK5ϑw
ny ;ٖVp]?`syZB=ܵTO}Qz䞗wST
Ϋs/lũ2yx ϣ-h#,fטu&C&MVT[jrkqƾ1SjA̡g8}`fZΊoJnf<;{^IUg"'FS[i|骠=ܸȌȁasp
gp~A@4vr*ޖ%/K,+WjZ J/F e2t"UReK-u6jy?iCJ~\PEn
j| &ԌõGó'&rY_zN|:kȟX7H(&Dq4&9AnLG##|kbF(r5 MbFR*rEƢ>E!JX]hzݺ֓?@Sne> +jcݒo2:808f8[zxk0T˪k%Fn!oE&Q06B
ކbY)5:{}wF55(w\&!g9ި&;;ZO?-kb]$q#({/^tF4ye3۬y[EYf_<oo`͋{wޤߐu]H
2=>쟯t
],O<{l=~|l'ۧ71$PPh_n(
K]ɕ;Iqe`_ƉW?W
~
퀰}'^sFo%쓙-*Ta5Ԋ qkʬz5CMM5̨7?50A8k栭Gs -D etƶӈP^@{ .#>נ]LQ%4
-h!Rȩ2-F^yZS1{ _4Yj]RɗxDnI̕{+urcN_c
33θ[ FO8#SrqaswsK'AjEmm\Y:h\fЧDUoAc=2v:Q&ulGN6_ؠs]mM]ȸ 6=ˣhQۢ.
ET"'J@4XJ7o]h.vfrȻ!d>
LاC2mYj˲BD䡙%ZH.^jlICTT,VGlb`Q;f1}w<;CKbks*95:3u;ck"hDd
MHHH d{y!lQDA bQ[zZ3:8ϼ`뜶}ݼ}y`6A$ơ)x1 6C ,tO_tC^AFkSCQ%hvyyס KMzM_Z;qt5,&}$vA*ş~HȰtf4)zg(efmC]E籃Uaό}>>=HSf&,tD1|HGWrtj0Cޥ5*c)?6>p$lZA\BߺsBɅ{H֡(h9
XAzFQg醐LXNfѕAG܋0uCKR>j$ir
ѺQ;&3/ɀw^zbջtG\Nxn G yMҏ)?FFԄj?Vrs:<7~JF+{\xaO2Q&?ZםlhR pcr:[I1ih++KlNDVg!NC7JHov1S"QYRKD&VUm%`Zk.]p|UM/%R
/zJgRyv톦hEwҖte^o8Kc&WY,{ƁB
Cq^GRܓnש
?xI;Ȏmfg,5=R-wiB`:ag
o #'c"%s2KQ?gig;-=y
~qľ
Dx8ne-9>}P{(śc$N%ݠzS?f@/& RybV? =GsFY`'/<DOHTixŭ1%)FnP#69Si5[,qlxv5H2`pOM
Y%YkJ9r2SP&-Zsb]kdTJŤ*]V[n(:W]Ot+eF͑R>pA&|KMh?(Z`#{ś;dRn`g?}JC3V;gUա&YYraxbvr@_~-C $>x'ca<,E2(.$J2xUCqretT69خʃm;-FlM.?嬩e7Js-l6:m*-wL
u:(t9(YIjNQɀj.VŬh| ȱ
BYRoj}ժ.Wv}jzq8A!([&bb|%%Ʋb+F,/?9S%栣<%!)u5X6p6/\/o)Ƹ^Yskӗ
Ί=ǔ/DG%4sFE]<,.s_kX!Q}NRjZy2zUua͝#\=2
M'dw8
d6"uխXu٪uւiJ,b$Iȅ\!$$4!4`
R[Qqi^b/:+w;vyΜyy+?9OF5UTTUm\ܶ,6PFrɞ
cƼ~h*{qgQ+7ˡ^N*]L#(s*moC!bװ)NS,K (F=dEWĞ`֛axt͉4Du9
L^KlGo=>ƶp͊(::"蚥lJ
%1+>{g>dlxYL*
T?'OmEAW0 n9
&wIv&Զ%0mb#wih^stӶ}t6|ٔc7IEg3og?t˙gaZFc;^@NcX䞛E.|snAq(~H['-n@PX y͔S?コٰgNoD <rE;5@p\ʪ@^hʞ۪G]-4U|Nc}V[ߩoy/Vm*;ED.&#KUm!Ħ$X
i%1'tZ$=<;x6C2Os˪ݚE